#### PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT7893659

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	SECURITY INTEREST

#### **CONVEYING PARTY DATA**

Name	Execution Date
BIOCRYST PHARMACEUTICALS, INC.	12/07/2020

#### **RECEIVING PARTY DATA**

Name:	ATHYRIUM OPPORTUNITIES III CO-INVEST 1 LP
Street Address:	505 FIFTH AVENUE
Internal Address:	FLOOR 18
City:	NEW YORK
State/Country:	NEW YORK
Postal Code:	10017

#### **PROPERTY NUMBERS Total: 15**

Property Type	Number
Patent Number:	11110092
Patent Number:	10689346
Patent Number:	11021458
Patent Number:	11464755
Patent Number:	11173159
Patent Number:	10622160
Patent Number:	10933066
Patent Number:	11066360
Patent Number:	11117867
Patent Number:	11192861
Patent Number:	11203574
Patent Number:	11230530
Application Number:	16987721
Patent Number:	11559515
PCT Number:	US2019059385

#### **CORRESPONDENCE DATA**

**Fax Number:** (310)551-8741

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

PATENT PATENT REEL: 063284 FRAME: 0001

507846523

**Phone:** 3105518755

Email: pto-cc@gibsondunn.com

Correspondent Name: MANDY ROBERTSON-BORA

Address Line 1: 2029 CENTURY PARK EAST, SUITE 4000 LOS ANGELES, CALIFORNIA 90067-3026

ATTORNEY DOCKET NUMBER: 12412-00023

NAME OF SUBMITTER: MANDY ROBERTSON-BORA

SIGNATURE: /mandy robertson-bora/

DATE SIGNED: 04/10/2023

#### **Total Attachments: 65**

source=2020-12-07 Security Interest#page1.tif

source=2020-12-07 Security Interest#page2.tif

source=2020-12-07 Security Interest#page3.tif

source=2020-12-07 Security Interest#page4.tif

source=2020-12-07 Security Interest#page5.tif

source=2020-12-07 Security Interest#page6.tif

source=2020-12-07 Security Interest#page7.tif

source=2020-12-07 Security Interest#page8.tif

source=2020-12-07 Security Interest#page9.tif

source=2020-12-07 Security Interest#page10.tif

source=2020-12-07 Security Interest#page11.tif

source=2020-12-07 Security Interest#page12.tif

source=2020-12-07 Security Interest#page13.tif

source=2020-12-07 Security Interest#page14.tif

source=2020-12-07 Security Interest#page15.tif

source=2020-12-07 Security Interest#page16.tif

source=2020-12-07 Security Interest#page17.tif

source=2020-12-07 Security Interest#page18.tif

source=2020-12-07 Security Interest#page19.tif

source=2020-12-07 Security Interest#page20.tif

source=2020-12-07 Security Interest#page21.tif

source=2020-12-07 Security Interest#page22.tif

source=2020-12-07 Security Interest#page23.tif

source=2020-12-07 Security Interest#page24.tif

source=2020-12-07 Security Interest#page25.tif

source=2020-12-07 Security Interest#page26.tif

source=2020-12-07 Security Interest#page27.tif

source=2020-12-07 Security Interest#page28.tif

source=2020-12-07 Security Interest#page29.tif

source=2020-12-07 Security Interest#page30.tif

source=2020-12-07 Security Interest#page31.tif

source=2020-12-07 Security Interest#page32.tif

source=2020-12-07 Security Interest#page33.tif

source=2020-12-07 Security Interest#page34.tif

source=2020-12-07 Security Interest#page35.tif

source=2020-12-07 Security Interest#page36.tif

source=2020-12-07 Security Interest#page37.tif
source=2020-12-07 Security Interest#page38.tif
source=2020-12-07 Security Interest#page39.tif
source=2020-12-07 Security Interest#page40.tif
source=2020-12-07 Security Interest#page41.tif
source=2020-12-07 Security Interest#page42.tif
source=2020-12-07 Security Interest#page43.tif
source=2020-12-07 Security Interest#page44.tif
source=2020-12-07 Security Interest#page45.tif
source=2020-12-07 Security Interest#page46.tif
source=2020-12-07 Security Interest#page47.tif
source=2020-12-07 Security Interest#page48.tif
source=2020-12-07 Security Interest#page49.tif
source=2020-12-07 Security Interest#page50.tif
source=2020-12-07 Security Interest#page51.tif
source=2020-12-07 Security Interest#page52.tif
source=2020-12-07 Security Interest#page53.tif
source=2020-12-07 Security Interest#page54.tif
source=2020-12-07 Security Interest#page55.tif
source=2020-12-07 Security Interest#page56.tif
source=2020-12-07 Security Interest#page57.tif
source=2020-12-07 Security Interest#page58.tif
source=2020-12-07 Security Interest#page59.tif
source=2020-12-07 Security Interest#page60.tif
source=2020-12-07 Security Interest#page61.tif
source=2020-12-07 Security Interest#page62.tif
source=2020-12-07 Security Interest#page63.tif
source=2020-12-07 Security Interest#page64.tif
source=2020-12-07 Security Interest#page65.tif

•	lr b		C	Ľ
	11 P	- 5 - 1		Γ.

OF

#### GRANT OF SECURITY INTEREST

IN

#### **PATENTS**

United States Patent and Trademark Office

December 7, 2020

Ladies and Gentlemen:

Please be advised that pursuant to the Security Agreement dated as of December 7, 2020 (as the same may be amended, modified, restated or supplemented from time to time, the "Security Agreement") by and among the Grantors party thereto (each a "Grantor" and collectively, the "Grantors") and ATHYRIUM OPPORTUNITIES III CO-INVEST 1 LP, as Administrative Agent (the "Administrative Agent") for the Secured Parties referenced therein, the undersigned Grantor has granted a continuing security interest in and continuing lien upon, any and all of its patents, patent licenses and patent applications, including those patents, patent licenses and patent applications set forth on Schedule 1 attached hereto to the Administrative Agent for the ratable benefit of the Secured Parties.

The undersigned Grantor and the Administrative Agent, on behalf of the Secured Parties, hereby acknowledge and agree that the security interest in the patents, patent licenses and patent applications of the undersigned Grantor, including those set forth on <u>Schedule 1</u> attached hereto (i) may only be terminated in accordance with the terms of the Security Agreement and (ii) is not to be construed as an assignment of any patent, patent license or patent application.

[Signature pages follow]

Very truly yours,

BIOCRYST PHARMACEUTICALS, INC., a Delaware corporation

Name: Authory Doyle
Title: Chief Financial Officer

[Signature Page - Notice of Grant of Security Interest in Patents]

ATHYRIUM OPPORTUNITIES III CO-INVEST 1 LP, a Delaware limited partnership, as Administrative Agent

By: Athyrium Opportunities Associates Co-Invest LLC, a Delaware limited liability company, its general partner

By: Lashida Odamo Name: Rashida Adams

Title: Authorized Signatory

[Signature Page - Notice of Grant of Security Interest in Patents]

100 A			4
No.	neda	116	1

See attached.

BioCryst	BioCryst	Owner of IP <sup>1</sup>
Substituted Cyclopentane and Cyclopentene Compounds Useful as Neuraminidase Inhibitors	Substituted Cyclopentane and Cyclopentene Compounds Useful as Neuraminidase Inhibitors	Tide of IP
Canada	Australia	Country/Region
2315262	2003212040	Owner of Title of IP Country/Region Patent or Application Status
Granted	Granted	Status
12/17/1998	12/17/1998	Filing Date <sup>2</sup>
12/17/2018 (expired)	12/17/2023	Projected Expiration Date <sup>3</sup>

Confidential

**REEL: 063284 FRAME: 0008** 

**PATENT** REEL: 063284 FRAME: 0009

BioCryst	BioCryst	Owner of
Substituted Cyclopentane and Cyclopentene Cyclopentene Compounds Useful as Neuraminidase Inhibitors	Substituted Cyclopentane and Cyclopentene Compounds Useful as Neuraminidase Inhibitors	Title of IP
Japan	EPO (European Patent Office)	Country/Region
4102022	<u></u> \$040094	Owner of   Patent or Application   Patent or Application   Status
Granted	Granted* *Validated in AT. BE, CH/LJ, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, and SE, plus AL, LT, LV, MK, RO, and SI	Status
12/17/1998	1.2/17/1998	Filing Date <sup>2</sup>
(expired)	* Supplementary Protection Certificates (SPCs) have been granted in available EU countries, extending this patent's protection for peramivir and pharmaceutically active salts thereof to 12/16/2023 in FR, GB, IE, and NL, to 12/17/2023 in AI, BE, CY, DK, FI, DE, HY, LV, LT, LU, PT, RO, SI, ES, and SE, and to 12/18/2023 in GR,	Projected Expiration Date <sup>3</sup>

1~3

Owner of	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date <sup>2</sup>	Projected Expiration Date <sup>3</sup>
					0	
BioCryst	Substituted  Cyclopentage and	Japan	5118502	Granted	12/17/1998	12/17/2018 (expired)
	Cyclopentane and					(expired)
	Compounds					
	Useful as					
	Neuraminidase					
	Inhibitors					
BioCryst	Substituted	neder	8896025	Granted	12/17/1998	12/17/2018
	Cyclopentane and					(expired)
	Cyclopentene					
	Compounds					
	Usciul as					
	Neuraminidase					
	Inhibitors					
BioCryst	Substituted	Poland	196674	Granted	12/17/1998	12/17/2018*
	Cyclopentane and					
	Cyclopentene					*SPC has been
	Compounds					granted, extending
	Useful as					projection for
	Neuraminidase					peramivic and
	Inhibitors					pharmaccutically
						thereof to
BioCryst	Substituted	Romania	121815	Granted	12/17/1998	12/17/2018
, i	Carloneantane and		;	!		(bynired)
	Cyclopentane and					(expired)
	Cycropenters					
	Compounds Useful as					
	Neuraminidase					
	Inhibitors					

Confidential

Owner of IP1	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date <sup>2</sup>	Projected Expiration Date <sup>3</sup>
BioCryst	Substituted Cyclopentane and	US	6,562,861	Granted	12/17/1998	12/16/2023
	Cyclopentene Compounds Useful as Neuraminidase					
	Neuraminidase Inhibitors					
BioCryst	Intravenous Antiviral	Australia	2013216632	Granted	02/12/2007	02/12/2027
	Treatments					
BioCryst	Intravenous	Australia	2016262644	Granted	02/12/2007	02/12/2027
	Treatments					
BioCryst	Intravenous	Brunci	RE/R/2019/0008	Granted	02/12/2007	02/12/2027
	Treatments			MY-166063-A,		
BioCryst	Intravenous	Brazil	P10707769-6	Pending	02/12/2007	02/12/2027
	Antiviral					
Bio C'myst	Texters (and our	Canada	3643360	Christia	02/32/2007	
DioClyst	Antiviral	Canada	2042200	Cranica	72/8/2/00/	020272021
	Treatments					
BioCryst	Intravenous	China	20151015375.7	Pending	02/12/2007	02/12/2027
	Antiviral					
	Treatments					

Confidential

BioCryst		BioCryst	Owner of							
Intravenous Antiviral Treatments	Intravenous Antiviral Treatments	Intravenous Autiviral Treatments	Intravenous Antiviral Treatments	Antiviral Treatments	Intravenous	Title of IP				
Mexico	Mexico	Malaysia	Republic of Korea	Republic of Korea	Japan	Indonesia	Hong Kong		Eurasia	Country/Region
371883 (MX/a/2014/010266)	328727	MY-166063-A (PI 20083086)	10-2019-7017311	10-1992585 (10-2018-7005451)	6073202	IDP000046170	16100369.5		025483	Patent or Application Number
Granted	Granted	Granted	Allowed	Granted	Granted	Granted	Pending	*Maintained in Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Moldova, Russian Federation, Tajikistan, and Turkmenistan	Granted*	Status
02/12/2007	02/12/2007	02/12/2007	02/12/2007	02/12/2007	02/12/2007	02/12/2007	02/12/2007		02/12/2007	Filing Date <sup>2</sup>
02/12/2027	02/12/2027	02/12/2027	02/12/2027	02/12/2027	02/12/2027	02/12/2027	02/12/2027		02/12/2027	Projected Expiration Date <sup>3</sup>

Confidential

Owner of			Patent or Application	***************************************		Projected Expiration
	1100 01 11	Country/Acgion		Status	Pag Date	DAIC
BioC weet	Intraconone	Maxim	\$00000/0000x	Dandino	20/12/2007	7,000/01/00
i,	Antivira			ť		
	Treatments					
BioCryst	Intravenous	New Zealand	570538	Granted	02/12/2007	02/12/2027
	Tragements					
Rigg	Intracionalis	Cinophora	145725	Grantad	00/10/2007	70000
	Amiriral	C. C.		1		
	Treatments					
BioCryst	Intravenous	South Africa	2008/09012	Granted	02/12/2007	02/12/2027
	Antiviral					
	Treatments					
BioCryst	Intravenous	Vietnam	1-2008-02252	Pending	02/12/2007	02/12/2027
	Antiviral					
	Treatments					***************************************
BioCryst	Antiviral	SU	8,778,997	Granted	02/12/2007*	05/07/2027
	Treatments					
BioCryst	Antiviral	SU	9,770,427	Granted	02/12/2007*	02/12/2027
	Treatments					
BioCryst	Antiviral	US	10,391,075	Granted	02/12/2007*	02/12/2027
	Treatments		(15/714,918)			
BioCryst	Antiviral	SU	16/533,283	Pending	02/12/2007*	02/12/2027
	Treatments					
BioCryst	Process for	SU	6,503,745	Granted	11/05/1999	11/05/2019
	Preparing					(expired)
	Substituted					
	Cyclopentane					
	Derivatives and					
	Novel Crystalline					
	Structures Thereof					

Owner of IP <sup>1</sup>	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date <sup>2</sup>	Projected Expiration Date <sup>3</sup>
BioCryst	Process for	Japan	4262920	Granted	06/09/2000	05/02/2021
,	Preparing Substituted	,				
	Cyclopentane					
	Derivatives and					
	Novel Crystalline					
	Structures Thereof					
BioCryst	Process for	Japan	4597237	Granted	06/09/2000	06/09/2020
	Preparing					(expired)
	Substituted					
	Cyclopentane					
	Derivatives and					
	Novel Crystalline					
	Structures Thereof					
BioCryst	Process for	Poland	213231	Granted	06/09/2000	06/09/2020
	Preparing					(expired)
	Substituted					
	Cyclopentane					
	Derivatives and					
	Novel Crystalline					
	Structures Thereof					
BioCryst	Process for	SU	6,576,786	Granted	06/09/2000*	06/09/2020
	Preparing					(expired)
	Substituted					
	Cyclopentane					
	Derivatives and					
	Novel Crystalline					
	Structures Thereof					

Owner of IP	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date <sup>2</sup>	Projected Expiration Date <sup>3</sup>
BioCryst	Process for	Japan	4532801	Granted	06/09/2000	06/09/2020
•	Preparing (-)- (1S.4R) N-	,				(expired)
	Protected 4-					
	Amino-2-					
	Cyclopentene-1-					
	Carboxylate					
	Esters					
BioCryst	Process for	Philippines	1-2000-001715	Granted	06/09/2000	06/09/2020
	Preparing (-)- (1S.4R) N-					(expired)
	Protected 4-					
	Amino-2-					
	Cyclopentene-1-					
	Carboxylate					
	Esters					
BioCryst	Process for	us	6,495,711	Granted	06/09/2000*	06/09/2020
	Preparing (-)-					(expired)
	Protected 4-					
	Amino-2-					
	Cyclopentene-1-					
	Esters					
BioCryst	Preparation of	SO	6,762,316	Granted	06/28/2000	06/28/2020
	Carlement					(natura)
	Cycropentage and					
	Cyclopentene Compounds and					
	Certain					
	Intermediates					

Confidential

(ospacou)						
iktako)					Nucleoside	
10/14/2017	10/14/1997*	Chanted	6,066,722	SU	Inhibitors of	BioCryst*
(expired)					Nucleoside Metabolism	
10/14/2017	10/14/1997*	Granted	5,985,848	SU	Inhibitors of	BioCryst*
					Metabolism	
(expired)				Korea	Nucleoside	,
10/14/2018	10/14/1998	Granted	637479	Republic of	Inhibitors of	BioCryst*
					Metabolism	
				,	Nucleoside	,
10/14/2023	10/14/1998	Granted	4451983	Japan	Inhibitors of	BioCryst*
					Metabolism	
(expired)				1	Nucleoside	•
10/14/2018	10/14/1998	Granted	HK1089159	Hong Kong	Inhibitors of	BioCryst*
		TValikaled in A.1. de, CH/LL CY, DK, FL, FR, DE, GB, GR, IE, IT, LU, MC, NL, PT, ES, and SE			Metabolism	
(expired)					Nucleoside	
10/14/2018	10/14/1998	Granted*	1023308	EPO	Inhibitors of	BioCryst*
					Metabolism	
(expired)	10/14/17/01	Chambon	EDECAS 1009 EMAS.	China	Nucleoside	DEALT AND
8106/77/01	10/14/1998	Granted	0 999000015000 12	China	Inhibitors of	Rian rest*
(expired)					Nucleoside	
10/14/2018	10/14/1998	Granted	ZL98811489	China	Inhibitors of	BioCryst*
					Metabolism	
(expired)					Nucleoside	
10/14/2018	10/14/1998	Granted	2305760	Canada	Inhibitors of	BioCryst*
					Metabolism	
(expired)					Nucleoside	,
10/14/2018	10/14/1998	Granted	749098	Australia	Inhibitors of	BioCryst*
Expiration Date	Filing Date <sup>2</sup>	Status	Patent or Application Number	Country/Region	Title of IP	Owner of IP:

Confidential

Owner of	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date <sup>2</sup>	Projected Expiration Date <sup>3</sup>
					,	
BioCryst*	Inhibitors of Nucleoside	US	6,228,847	Granted	10/14/1997*	10/14/2017 (expired)
BioCres*	Inhibitors of	Z.	6 492 347	pataka) 	10/14/1997*	10/14/2017
rate of the	Nucleoside Metabolism	Ç	Sy TV Arryse S C	Cracou	X 57 % To # 0 0 0 0	(expired)
BioCryst*	Inhibitors of	US	6,803,455	Granted	10/14/1997*	10/14/2017
	Nucleoside Metabolism					(expired)
BioCryst*	Inhibitors of	US	7,211,653	Granted	10/14/1997*	10/14/2017
	Nucleoside Metabolism					(expired)
BioCryst*	Inhibitors of	US	7,390,890	Granted	10/14/1997*	10/14/2017
	Nucleoside					(expired)
BioCryst*	Process for	Australia	776540	Granted	04/07/2000	04/07/2020
,	Preparing Inhibitors of					(expired)
	Nucleoside					
	Metabolism					
BioCryst*	Process for	Canada	2368095	Granted	04/07/2000	04/07/2020
	Inhibitors of					(expired)
	Nucleoside					
	Metabolism					
BioCryst*	Process for	Canada	2634299	Granted	04/07/2000	04/07/2020
	Preparing					(expired)
	lubilotors of					
	Matabalian					
	Metabonsm					

Confidential

BioCryst* Process for Preparing Inhibitors of Nucleoside	BioCryst* Process for Preparing Inhibitors of Nucleoside Metabolism	BioCryst* Process for Preparing Inhibitors of Nucleoside Metabolism	BioCryst* Process for Preparing Inhibitors of Nucleoside Metabolism	BioCryst* Process for Preparing Inhibitors of Nucleoside Metabolism	Owner of Title of IP
EPO	China	China	China	Canada	Country/Region
1165364	200610148465.7	100344630C	1196704C	2696826	Patent or Application Number
Granted*  *Validated in AL, AT, BE, CH/LI, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LT, LU, LV, MC,	Granted	Granted	Granted	Granted	Status
04/07/2000	04/07/2000	04/07/2000	04/07/2000	04/07/2000	Filing Date <sup>2</sup>
04/07/2020 (expired)	04/07/2020 (expired)	04/07/2020 (expired)	04/07/2020 (expired)	04/07/2020 (expired)	Projected Expiration Date <sup>3</sup>

Confidential

BioCryst*	BioCryst*	BioCryst*	BioCryst*	BioCryst*	Bio€ryst*	Owner of
Process for Preparing Inhibitors of Nucleoside Metabolism	Process for Preparing Inhibitors of Nucleoside Metabolism	Process for Preparing Inhibitors of Nucleoside Metabolism	Process for Preparing Inhibitors of Nucleoside Metabolism	Process for Preparing Inhibitors of Nucleoside Metabolism	Process for Preparing Inhibitors of Nucleoside Metabolism	Title of IP
Republic of Korea	Japan	Japan	Hong Kong	Hong Kong	EPO	Country/Region
0755110	5070237	4430247	HK1116472	HK 1088310	2077268	Patent or Application Number
Granted	Granted	Granted	Granted	Granted	Granted*  *Validaled in AL. AT, BE, CHALL CY, DE, DK, ES, FLFR, GB, GR, IE, ET, LT, LU, LV, MC, MK, NL, PT, RO, SE, and SI	Status
04/67/2000	04/07/2000	04/67/2000	04/07/2000	04/07/2000	04/07/2000	Filing Date <sup>2</sup>
04/07/2020 (expired)	04/07/2020 (expired)	04/07/2025	04/07/2020 (expired)	04/07/2020 (expired)	04/07/2020 (expired)	Projected Expiration Date <sup>3</sup>

Confidential

Owner of	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date <sup>2</sup>	Projected Expiration Date <sup>3</sup>
					Q	
BioCryst*	Process for	Republic of	0827118	Granted	04/07/2000	04/07/2020
4	Preparing	Korea				(expired)
	Inhibitors of					7
	Nucleoside					
	Metabolism					
BioCryst*	Process for	New Zealand	514660	Granted	04/07/2000	04/07/2020
	Preparing					(expired)
	Inhibitors of					
	Nucleoside					
	Metabolism					
BioCryst*	Process for	SU	6,693,193	Granted	04/07/2000	04/07/2020
	Preparing 2-					(expired)
	Pyrrolidinyl-H4-					
	Pyrrolo[3,2-d]					
	Pyrimidine					
	Inhibitors of					
	Nucleoside					
	Metabolism					
BioCryst*	Process for	SU	7,022,852	Granted	04/07/2000	08/16/2020
	Preparing					(expired)
	Inhibitors of					
	Nucleoside					
	Metabolism					
BioCryst*	Process for	SU	7,211,677	Granted	04/07/2000	04/07/2020
	Preparing					(expired)
	Inhibitors of					
	Nucleoside					
	Metabolism					

Confidential

Owner of	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date <sup>2</sup>	Projected Expiration Date <sup>3</sup>
					į	
BioCryst*	Process for	US	7,405,297	Granted	04/07/2000	04/07/2020
,	Preparing					(expired)
	Inhibitors of					-
	Nucleoside					
	Metabolism					
BioCryst	Methods of	Australia	2008335167	Granted	12/10/2008	12/10/2028
	Treating					
	Hematologic					
	Cancers					
BioCryst	Methods of	Canada	2708606	Granted	12/10/2008	12/10/2028
	Treating					
	Hematologic					
	Cancers					
BioCryst	Methods of	China	200880126808.7	Granted	12/10/2008	12/10/2028
	Treating					
	Hematologic					
	Cancers					
BioCryst	Methods of	China	2L201410039689.9	Granted	12/10/2008	12/10/2028
	Treating					
	Hematologic					
	Cancers					
BioCryst	Methods of	Eurasia	018415	Granted*	12/10/2008	12/10/2028
	Treating					
	Hematologic			* Maintained in Russian		
	Cancers			rederation		
BioCryst	Methods of	EPO	2564846	Granted*	12/10/2008	12/10/2028
	Treating					
	Hematologic			*Validated in FR, DE,		
	Cancers			GB, IT, NL, ES		

ВіоСпуя:*	BioCryst*	BioCryst*	BioCryst	BioCryst	BioCryst		Bio€rysŧ	Owner of Ip:
Inhibitors of Nucleoside Phosphorylases and Nucleosidases	Inhibitors of Nucleoside Phosphorylases and Nucleosidases	Inhibitors of Nucleoside Phosphorylases and Nucleosidases	Methods of Treating Hematologic Cancers	Methods of Treating Hematologic Cancers	Methods of Treating Hematologic Cancers	Methods of Treating Hematologic Cancers	Methods of Treating Hematologic Cancers	Title of IP
Canada	Brazil	Australia	Sn	New Zealand	Republic of Korea	Japan	Indía	Country/Region
2496698	BR20030013664.7	258911	16/400,414	601072	10-1545367	5543362	2383/KOLNP/2010	Patent or Application Number
Granted	Pending	Granted	Pending	Granted	Granted	Granted	Pending	Status
08/21/2003	08/21/2003	08/21/2003	12/10/2008	12/10/2008	12/10/2008	12/10/2008	12/10/2008	Filing Date <sup>2</sup>
08/21/2023	08/21/2023	08/21/2023	12/10/2028	<b>1</b> 2/10/2028	12/10/2028	12/10/2028	12/10/2028	Projected Expiration Date <sup>3</sup>

Confidential

**PATENT** REEL: 063284 FRAME: 0023

Owner of	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date <sup>2</sup>	Projected Expiration Date <sup>3</sup>
BioCryst*	Inhibitors of Nucleoside Phosphorylases and Nucleosidases	China	ZL03824354.7	Granted	08/21/2003	08/21/2023
BioCryst*	Inhibitors of Nucleoside	EPO	1539783	Granted*	08/21/2003	08/21/2023
	Phosphorylases and Nucleosidases			*Validated in AT, BE, BG, CY, CZ, DK, EE, ET, FR, DE, GR, HU, IE, IT, LU, MC, PT, RO, SK, SI, ES, SE, CH/LL TR, GB, and NL		
BíoCryst*	Inhibitors of Nucleoside Phosphorylases and Nucleosidases	Hong Kong	HK1085219	Granted	08/21/2003	08/21/2023
BioCryst*	Inhibitors of Nucleoside Phosphorylases	India	244822	Granted	08/21/2003	08/21/2023
BioCryst*	Inhibitors of Nucleoside Phosphorylases and Nucleosidases	Japan	4682314	Granted	08/21/2003	08/21/2023
BioCryst*	Inhibitors of Nucleoside Phosphorylases and Nucleosidases	Republic of Korea	10-1081226	Granted	08/21/2003	08/21/2023
BìoCryst*	Inhibitors of Nucleoside Phosphorylases and Nucleosidases	New Zcaland	538368	Granted	08/21/2003	08/21/2023

<u>س</u>

Owner of IP <sup>1</sup>	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date <sup>2</sup>	Projected Expiration Date <sup>3</sup>
					,	
BioCryst*	Inhibitors of	Russian	2330042	Granted	08/21/2003	08/21/2023
,	Nucleoside	Federation.				
	Phosphorylases					
	and Nucleosidases					
BioCryst*	Inhibitors of	Singapore	110552	Granted	08/21/2003	08/21/2023
	( acicosido					
	Phosphorylases					
	and Nucleosidases					
BioCryst*	5H-Pyrrolo[3,2-d]	SU	7,553,839	Granted	08/21/2003	12/03/2023
	Pyrimidine					
	Inhibitors of					
	Nucleoside					
	Phosphorylases					
	and Nucleosidases					
BioCryst*	Fused Pyrimidines	US	8,173,662	Granted	08/21/2003	09/01/2024
	as Inhibitors of					
	Nucleoside					
	Phosphorylases					
	and Nucleosidases					
BioCryst	Useful	Australia	2010230008	Granted	03/24/2010	03/24/2030
	Phamaceutical					
	Salts of 7-[(3R,					
	4R)-3-Hydroxy-4-					
	Hydroxymethyl-					
	Pyrrolidin-1-					
	Ylmethyll-					
	3,5-Dihydro-					
	Pyrrolo[3,2-					
	d]Pyrimidin-4-					
	One					

Owner of IP:	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date <sup>2</sup>	Projected Expiration Date <sup>3</sup>
D) A Character	15£.}	<b>5</b>	o kesour ja	D.a.din.	03/24/2010	0505/2010
Bio€ryst	Useful Pharmaceutical Salts of 7-[(3R, 4R)-3-Hydroxymethyl- Pyrrolidin-1- Ylmethyl - 3,5-Dihydro- Pyrrolo[3,2- d]Pyrimidin-4- One Useful Pharmaceutical Salts of 7-[(3R, 4R)-3-Hydroxy-4- Hydroxymethyl- Pyrrolidin-1- Ylmethyl]-	Brazil Canada	PI 1006534-2 2755950	Pending  Granted	03/24/2010	03/24/2030
BioCryst	Useful Pharmaceutical Salts of 7-[(3R, 4R)-3-Hydroxy-4- Hydroxymethyl- Pyrrolidin-1- Ylmethyl]- 3,5-Dihydro- Pyrrolo[3,2- d]Pyrinidin-4- One	Canada	2755950	Granted	03/24/2010	03/24/2030

<u>....</u>

Confidential

**REEL: 063284 FRAME: 0025** 

BioCryst   Useful   Pharmaceutical   Pharmaceutical   Salts of 7-[(3R, 4R)-3-Hydroxy   Hydroxymethyl   Pyrrolidin-1-   Ylmethyl  -	BioCryst Useful Pharmaceutical Pharmaceutical Salts of 7-[(3R, 4R)-3-Hydroxy Hydroxymethyl Pyrrolidin-1- Ylmethyl]- 3,5-Dihydro- Pyrrolo[3,2- d]Pyrimidin-4- One	Owner of Title of IP
Useful Pharmaceutical Salts of 7-[(3R, 4R)-3-Hydroxy-4- Hydroxymethyl- Pyrrolidin-1- Ylmethyl]- 3,5-Dihydro- Pyrrolo[3,2-	Useful Pharmaceutical Salts of 7-[(3R, 4R)-3-Hydroxy-4- Hydroxymethyl- Pyrrolidin-1- Ylmethyl - 3,5-Dihydro- Pyrrolo[3,2- d]Pyrimidin-4- One	IP
Eurasia	China	Country/Region
020931	ZL201080022925.6	Patent or Application Number
Granted*  *Maintained in Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Moldova, Russtan Federation, Tajikistan, and Turkmenistan	Granted	Status
03/24/2010	03/24/2010	Filing Date <sup>2</sup>
03/24/2030	03/24/2030	Projected Expiration Date <sup>3</sup>

**7** 

Owner of	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date <sup>2</sup>	Projected Expiration Date <sup>3</sup>
BioCryst	Useful	EPO	2411394	Granted*	03/24/2010	03/24/2030
	Pharmaceutical Salts of 7.1/3R			*Validated in EX IT		
	4R)-3-Hydroxy-4-			PL, TR, CHALL, IE, FR,		
	Hydroxymethyl-			DE, and GB		
	Pyrrolidin-1-					
	Ylmethyl)-					
	3,5-Dibydro-					
	Pyrrolo[3,2~					
	d]Pyrimidin-4-					
	One					
BioCryst	Uscful	Hong Kong	1170486	Granted	03/24/2010	03/24/2030
	Pharmaceutical Salts of 7-1/3R					
	4R)-3-Hydroxy-4-					
	Hydroxymethyl-					
	Pyrrolidin-1-					
	Ylmethyl)-					
	3,5-Dihydro-					
	Pyrrolo[3,2-					
	d]Pyrimidin-4-					
	One					

**PATENT REEL: 063284 FRAME: 0027** 

20

Owner of	Tide of IP	Country/Region	Patent or Application Number	Status	Filing Date <sup>2</sup>	Projected Expiration Date <sup>3</sup>
					G	
Bio€ryst	Useful Pharmaceutical Salts of 7-[(3R, 4R)-3-Hydroxy-4- Hydroxymethyl- Pyrrolidin-1- Ylmethyl - 3,5-Dihydro- Pyrrolo[3,2- d]Pyrimidin-4- One	India	312836 (8012/DELNP/2011)	Granted	03/24/2010	03/24/2030
BioCryst	Useful Pharmaceutical Salts of 7-[(3R, 4R)-3-Hydroxy-4- Hydroxymethyl- Pyrrolidin-1- Ylmethyl]- 3,5-Dihydro- Pyrrolo[3,2- d]Pyrimidin-4- One	İsracl	215298	Granted	03/24/2010	03/24/2030

Confidential

Owner of Ip <sup>1</sup>	BioCryst	BioCryst
of Title of IP		t Useful
Country/Region	Japan	Republic of Korea
Owner of   Patent or Application   Patent or Application   Status	5766687	10-1763672
Status	Granted	Granted
Filing Date <sup>2</sup>	03/24/2010	03/24/2010
Projected Expiration Date <sup>3</sup>	03/24/2030	03/24/2030

BioCryst	BioCryst	Owner of
Useful Pharmaceutical Salts of 7-[(3R, 4R)-3-Hydroxy-4- Hydroxymethyl- Pyrrolidin-1- Ylmethyl - 3,5-Dihydro- Pyrrolo[3,2- d]Pyrimidin-4-	Useful Pharmaceutical Salts of 7-[(3R, 4R)-3-Hydroxy-4- Hydroxymethyl- Pyrrolidin-1- Ylmethyl - 3,5-Dihydro- Pyrrolo[3,2- d]Pyrinidin-4- One	Tide of IP
New Zealand	Mexico	Country/Region
595590	318219	Owner of Title of IP Country/Region Patent or Application Status
Granted	Granted	Status
03/24/2010	03/24/2010	Filing Date <sup>2</sup>
03/24/2030	03/24/2030	Projected Expiration Date <sup>3</sup>

Owner of	Title of IP	Country/Region	Owner of Title of IP Country/Region Patent or Application Status	Status	
BioCryst	Useful Pharmaceutical Pharmaceutical Salts of 7-[(3R, 4R)-3-Hydroxy-4- Hydroxymethyl- Pyrrolidin-1- Ylmethyl - 3,5-Dihydro- Pyrrolo[3,2- d]Pyrimidin-4- One	Philippines	1-2011-501900		Granted
BioCryst	Useful Pharmaceutical Salts of 7-[(3R, 4R)-3-Hydroxy-4- Hydroxymethyl- Pyrrolidin-1- Ylmethyl]- 3,5-Dihydro- Pyrrolo[3,2- d]Pyrimidin-4-	Russian Federation	2489435		Granted

Confidential

Owner of IP1	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date <sup>2</sup>	Projected Expiration Date <sup>3</sup>
BioCryst BioCryst	Useful Pharmaceutical Salts of 7-[(3R, 4R)-3-Hydroxy-4- Hydroxymethyl- 3,5-Dihydro- Pyrrolo[3,2- d]Pyrimidin-4- One Useful Pharmaceutical Salts of 7-[(3R, 4R)-3-Hydroxy-4- Hydroxymethyl- Pyrrolidin-1-	Singapore US	174517 8,501,753	Granted Granted	03/24/2010	03/24/2030
	Pyrrolidin-1- Ylmethyl]- 3,5-Dihydro- Pyrrolo[3,2- d]Pyrimidin-4- One					

PATENT REEL: 063284 FRAME: 0033

Owner of IPs	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date <sup>2</sup>	Projected Expiration Date <sup>3</sup>
BioCryst	Useful	Vietnam	₩ \$4 \$6	Granted	03/24/2010	03/24/2030
	Pharmaccutical Salts of 7-1(3R,					
	4R)-3-Hydroxy-4- Hydroxymethyl-					
	Pyrrolidin-1-					
	Ylmethyl)-					
	3,5-Dihydro-					
	d]Pyrimidin-4-					
	One					
BioCryst*	Acyclic Amine	Australia	2007293774	Granted	09/07/2007	09/07/2027
	Inhibitors of					
	Nucleoside					•••••
	Phosphorylases					
j }	and rivalorases	2		,		
Rio(Livst*	Acyclic Amine	Canada	2662628	Granted	09/87/2007	09/07/2027
	luhibitors of					
	Nucleoside					
	Phosphorylases					
	and Hydrolases					
BioCryst*	Acyclic Amine	China	200780040294.9	Granted	09/07/2007	09/07/2027
	limbitors of					
	Nucleoside					
	Phosphorylases					
	and Hydrolases					****

**PATENT** REEL: 063284 FRAME: 0034

Owner of IP <sup>1</sup>	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date <sup>2</sup>	Projected Expiration Date <sup>3</sup>
BioCryst*	Acyclic Amine Inhibitors of Nucleoside	EPO	2057165	Granted* *Validated in Al., AT,	09/07/2007	09/07/2027
	Phosphorylases and Hydrolases			BE, BA, BG, HR, CY, CZ, DK, EE, FI, FR, GE, GR, HU, IS, IE, FI, LV, LT, LU, MT, MK, MC, FL, FT, RO, RS, SK, St, ES, SE, CH/L1, TR, GB, and NL		
Ві́оСіу∕sі*	Acyclic Amine Inhibitors of Nucleoside Phosphorylases and Hydrolases	Hong Kong	1131612	Granted	09/07/2007	09/07/2027
BioCryst*	Acyclic Amine Inhibitors of Nucleoside Phosphorylases and Hydrolases	Ĭndia	287760	Granted	09/87/2007	09/07/2027
BioCryst*	Acyclic Amine Inhibitors of Nucleoside Phosphorylases and Hydrolases	Japan	5388067	Granted	09/87/2007	09/07/2027
BioCryst*	Acyclic Amine Inhibitors of Nucleoside Phosphorylases and Hydrolases	Republic of Korea	10-1433621	Granted	09/07/2007	09/07/2027

Confidential

27

Owner of IP1	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date <sup>2</sup>
BioCryst*	Acyclic Amine	New Zealand	575365	Granted	09/07/2007
вюскаг	Acyclic Amine Inhibitors of Nucleoside	New Zealand	979360	Granted	09/0//200
	Phosphorylases				
	and Hydrolases				
BioCryst*	Acyclic Amine	US	8,853,224	Granted	09/07/2007
•	Inhibitors of				
	Nucleoside				
	Phosphorylases				
	and Hydrolases				
BioCryst	Inhibiting T-Cell Proliferation	us	6,660,719	Granted	12/17/2001*
BioCryst	Process for the	US	7.230.119	Granted	08/25/2005*
,	Preparation of				
	Substituted				
	Pyrrolidine				
	Derivatives and				
	Intermediates				
BioCryst	Carboxy Pyrrole,	US	6,972,331	Granted	04/23/2003*
	Process of				
	Preparing and Use				
	as Precursor				
BioCryst	Deazaguanine	SO	6,458,799	Granted	05/04/2001*
	Analog,				
	Preparation				
	Thereof and Use				
	Thereof				
BioCryst	Preparation of	SU	6,780,993	Granted	02/19/2003*
	Deazaguanine				
	Analog				

Confidential

**PATENT REEL: 063284 FRAME: 0035** 

28

Preparation of the property of	_	ВюСгузт Нера Тъек	BioCryst Hepatitis   Therapies	BioCryst Meth Prepx Deaz Deni	Furoj and Thier	BioCryst Theraper	BioCryst Antiviral Nucleosi	BioCryst Antiviral Nucleos Analogs	Owner of Title
Preparation Thereof and Use as labilitors of RNA Viral	Hepatitis C Therapies	Hepatitis C Therapies	Hepatitis C Therapies	Methods for the Preparation of 9- Deazaparine Derivatives	Furopyrimidines and Thienopyrimidine s	Therapeutic	Antiviral Nucleoside	Antiviral Nucleoside Analogs	Title of IP
ç	US	S	Japan	us		US	US	Mexico	Country/Region
7,300,002	8,163,703	7,514,410	5107228	8,344,132		7,429,571	8,440,813	300594	Patent or Application Number
Classica	Granted	Granted	Granted	Granted		Granted	Granted	Granted	Status
1.11 8.49 52XXX.	10/28/2005	10/28/2005	10/28/2005	06/21/2006		10/28/2005	01/11/2008	01/11/2008	Filing Date <sup>2</sup>
1 42 2 81 420 424	10/14/2026	10/14/2026	10/28/2025	03/28/2028		07/17/2026	11/16/2028	01/11/2028	Projected Expiration Date <sup>3</sup>

Owner of IP1	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date <sup>2</sup>	Projected Expiration Date <sup>3</sup>
BioCryst	Tetrahydrofuro [3 4-D] Dioxolane Compounds for	Sn	8,242,085	Granted	05/08/2008	11/16/2028
	Use in the Treatment of Viral Infections and Cancer					
BioCryst	Aza Nucleosides,	SU	7,560,434	Granted	06/22/2005*	08/06/2026
	Preparation Thereof and Use					
	as Inhibitors of					
	Polymerases					
BioCryst	Methods and	Australia	2011315902	Granted	10/14/2011	10/14/2031
	Compositions for Inhibition of					
	Polymerase					
BioCryst	Methods and	Australia	2017200471	Granted	10/14/2011	10/14/2031
	Compositions for Inhibition of					
	Polymerase					
BioCryst	Methods and	Brazil	BR112013009029-4	Pending	10/14/2011	10/14/2031
	Unhibition of					
	Polymerase					
BioCryst	Methods and	Canada	2813783	Granted	10/14/2011	10/14/2031
	Compositions for					
	Inhibition of					
	Polymerase					

Confidential

BioCryst	BioCryst	Bio€ryst	BioCryst	BioCryst	Owner of IP
Methods and Compositions for Inhibition of Polymerase	Methods and Compositions for Inhibition of Polymerase	Methods and Compositions for Inhibition of Polymerase	Methods and Compositions for Inhibition of Polymerase	Methods and Compositions for Inhibition of Polymerase	Title of IP
Hong Kong	EPO	EPO	EPO	China	Country/Region
HK1191565	3345605 (17196354.9)	2898885	2627334	201180059786.9	Patent or Application Number
Gramed	Granted*  *Validated in GB, FR, DE, NL, CH/LI, IE, and BE	Granted*  *Validated in AL, AT, BE, BG, CH/LI, CY, CZ, DR, DK, EE, ES, FI, FR, GB, GR, HR, HU, EE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NQ, FL, PT, RO, RS, SE, SI, SK, SM, and TR	Granted*  *Validated in AL, AT, BE, BG, CH/LI, CY, DE, DR, EE, ES, FI, FR, GB, GR, HU, IE, IS, ET, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SM, and TR	Granted	Status
10/14/2011	10/14/2011	10/14/2011	10/14/2011	10/14/2011	Filing Date <sup>2</sup>
10/14/2031	10/14/2031	10/14/2031	10/14/2031	10/14/2031	Projected Expiration Date <sup>3</sup>

Confidential

BioCryst	BioCryst	BioCryst	BioCryst	BioCryst	BioCryst	BioCryst	BioCryst	Owner of IP:
Methods and Compositions for Inhibition of Polymerase	Methods and Compositions for Inhibition of Polymerase	Methods and Compositions for Inhibition of Polymerase	Methods and Compositions for Inhibition of	Methods and Compositions for Inhibition of Polymerase	Methods and Compositions for Inhibition of Polymerase	Methods and Compositions for Inhibition of Polymerase	Methods and Compositions for Inhibition of Polymerase	Title of IP
Russian Federation	Mexico	Republic of Korea	Japan	[sræ]	India	Hong Kong	Hong Kong	Country/Region
2599013	348759	10-1850925 (10-2013-7012318)	5902698	225672	201838039907	1257363 (18116571.3)	HK1212914 (16100950,0)	Patent or Application Number
Granted	Granted	Granted	Granted	Granted	Pending	Granted	Granted	Status
10/14/2011	10/14/2011	10/14/2011	10/14/2011	10/14/2011	10/14/2011	10/14/2011	10/14/2011	Filing Date <sup>2</sup>
10/14/2031	10/14/2031	10/14/2031	10/14/2031	10/14/2031	10/14/2031	10/14/2031	10/14/2031	Projected Expiration Date <sup>3</sup>

Confidential

Owner of Ips  BioCryst  BioCryst		Country/Region Russian Federation Russian Federation	Patent or Application Number  2718690 (2016134401)  2020111042	Status  Granted  Pending	Filing Date <sup>2</sup> 10/14/2011 10/14/2011
BioCryst BioCryst	Methods and Compositions for Inhibition of Polymerase Methods and Compositions for Inhibition of Polymerase	Russian Federation US	20201110 <b>4</b> 2 9,492,452	Pending Granted	
BioCryst BioCryst	Methods and Compositions for Inhibition of Polymerase Methods and Compositions for Inhibition of Polymerase	Sn	\$0,022,375 (15/337,320) 10,420,769 (16/013,059)	Granted Granted	ಮ ದಿ
BioCryst	Methods and Compositions for Inhibition of Polymerase	υs	16/543,079	Pending	g
BioCryst	Methods and Compositions for Treatment of Zika Virus Infection	Australia	2017229105	Pending	e e e e e e e e e e e e e e e e e e e
BioCryst	Methods and Compositions for Treatment of Zika Virus Infection	Canada	3016588	Pending	gn

Confidential

BioCryst	BioCryst	BioCryst	BioCryst	BioCryst	BioCryst	BioCryst	BioCryst	Owner of Ip <sup>1</sup>
Compositions and Methods for Inhibiting Viral Polymerase	Methods and Compositions for Treatment of Zika Virus Infection	Methods and Compositions for Treatment of Zika Virus Infection	Methods and Compositions for Treatment of Zika Virus Infection	Methods and Compositions for Treatment of Zika Virus Infection	Methods and Compositions for Treatment of Zika Virus Infection	Methods and Compositions for Treatment of Zika Virus Infection	Methods and Compositions for Treatment of Zika Virus Infection	Title of IP
Australia	Taiwan	US	Sn	Mexico	Japan	Hong Kong	EPO	Country/Region
2013249344	106107257	16/692,816	10,512,649 (16/082,437)	MX/A/2018/010707	2018-566196	19126879,6	17763837.6	Patent or Application Number
Granted	Pending	Allowed	Granted	Pending	Pending	Pending	Pending	Status
04/17/2013	03/06/2017	03/06/2017	03/06/2017	03/06/2017	03/06/2017	03/06/2017	03/06/2017	Filing Date <sup>2</sup>
04/17/2033	03/06/2037	03/06/2037	03/06/2037	03/06/2037	03/06/2037	03/06/2037	03/06/2037	Projected Expiration Date

Confidential

BioCryst	BioCryst	BioCryst	BioCryst	BioCryst	BioCryst	BioCryst	BioCryst	Owner of IP <sup>1</sup>
Compositions and Methods for Inhibiting Viral Polymerase	Compositions and Methods for Inhibiting Viral Polymerase	Compositions and Methods for Inhibiting Viral Polymerase	Compositions and Methods for Inhibiting Viral Polymerase	Compositions and Methods for Inhibiting Viral Polymerase	Compositions and Methods for Inhibiting Viral Polymerase	Compositions and Methods for Inhibiting Viral Polymerase	Compositions and Methods for Inhibiting Viral Polymerase	Title of IP
India	Israc1	Hong Kong	EPO	Масан	China	Canada	Brazil	Country/Region
308689 (2525/KOLNP/2014)	235123	HK1206627 (15107309.4)	2838535 (13778292.6)	J/003406	ZL201380031507.7	2870722	BR112014025909-7	Patent or Application Number
Granted	Granted	Granted	Granted*  *Validated in GB, FR, DE, NL, CH/LI, EE, and EE	Granted (based on ZL201380031507.7, above)	Granted	Granted	Pending	Status
04/17/2013	04/17/2013	04/17/2013	04/17/2013	04/17/2013	04/17/2013	04/17/2013	04/17/2013	Filing Date <sup>2</sup>
04/17/2033	04/17/2033	04/17/2033	04/17/2033	04/17/2033	04/17/2033	04/17/2033	04/17/2033	Projected Expiration Date

Confidential

Owner of	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date <sup>2</sup>	Projected Expiration Date <sup>3</sup>
2	2	*	****		2	
BioCryst	Compositions and Methods for Inhibiting Viral Polymerase	Japan	6559266 (2018-7131)	Granted	04/17/2013	04/17/2033
BioCryst	Compositions and Methods for Inhibiting Viral Polymerase	Republic of Korea	10-2014-7032192	Allowed	04/17/2013	04/17/2033
BioCryst	Compositions and Methods for Inhibiting Viral Polymerase	Republic of Korea	10-2020-7016520	Pending	04/17/2013	04/17/2033
BioCryst	Compositions and Methods for Inhibiting Viral Polymerase	Mexico	363270 (MX/a/2014/012525)	Granted	04/17/2013	04/17/2033
BioCryst	Compositions and Methods for Inhibiting Viral Polymerase	Russian Federation	2654482 (2014145857)	Granted	04/17/2013	04/17/2033
BioCryst	Compositions and Methods for Inhibiting Viral Polymerase	US	9,580,428	Granted	04/17/2013	04/17/2033
BioCryst	Compositions and Methods for Inhibiting Viral Polymerase	Argentina	20130101229	Pending	04/16/2013	04/16/2033
ВюСпуя	Compositions and Methods for habibiting Viral Polymerase	Taiwan	1664180 (102113674)	Granted	04/17/2013	04/16/2033

Confidential

,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,						*
Owner of	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date <sup>2</sup>	Expiration Date <sup>3</sup>
BioCryst	Anti-Influenza	Australia	2014265483	Granted	05/14/2014	05/14/2034
	Compositions and Methods					
BioCryst	Anti-Influenza	Canada	2911424	Pending	05/14/2014	05/14/2034
	Compositions and Methods					
BioCryst	Anti-Influenza	EPO	2996685	Granted*	05/14/2014	05/14/2034
	Compositions and		(14798158.3)			
	Methods			*Validated in GB, FR, DE, NL, CH/LI, IE, and		
<u> </u>				250		
Bio€ryst	Anti-Influenza Compositions and	Hong Kong	(16110778 9)	Granted	05/14/2014	05/14/2034
	Methods					
BioCryst	Anti-Influenza	Japan	6417568	Granted	05/14/2014	05/14/2034
	Compositions and		(2016-514060)			
BioCryst	Anti-Influenza	US	9,499,554	Granted	05/14/2014	05/14/2034
,	Compositions and					
	Methods					
BioCryst	Biaryl	Australia	2002213393	Granted	10/22/2001	10/22/2021
	Compounds as					
	Serine Protease					
	Inhibitors					
BioCryst	Biaryl	Canada	2426430	Granted	10/22/2001	10/22/2021
	Compounds as					
	Serine Protease					
	Inhibitors					

Confidential

Owner of	Title of IP	Country/Region	Patent or Application Number	Status	Filine Date <sup>2</sup>	Projected Expiration Date <sup>3</sup>
					0	
BioCryst	Biaryl Compounds as	Odä	1383731	Granted*	10/22/2001	10/22/2021
	Compounds as Serinc Protease Inhibitors			* Validated in AT, BE, CH/LI, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, and TR		
BioCryst	Biaryl	Hong Kong	HK 1062676	Granted	10/22/2001	10/22/2021
	Compounds as Serine Protease					
	Inhibitors					
BioCryst	Biaryl Compounds as	Israel	155202	Granted	10/22/2001	10/22/2021
	Serine Protease Inhibitors					
BioCryst	Biaryl	Israel	222773	Granted	10/22/2001	10/22/2021
	Compounds as					
	Serine Protease Inhibitors					
BioCryst	Biaryl Compounds as Serine Protease	Japan	4342178	Granted	10/22/2001	10/22/2021
BioCryst	Biaryl	Mexico	243423	Granted	10/22/2001	10/22/2021
	Compounds as					
	Serine Protease					
	Inhibitors					
BioCryst	Biary	New Zealand	526003	Granted	10/22/2001	10/22/2021
	Compounds as					
	Serine Protease					
	inhibitors					

Confidential

Owner of	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date <sup>2</sup>	Projected Expiration Date <sup>3</sup>
		A			Q	
BioCryst	Biaryl Compounds as	Philippines	1-2003-500984	Granted	10/22/2001	10/22/2021
	Serine Protease Inhibitors					
BioCryst	Biaryl Compounds as	Singapore	98519	Granted	10/22/2001	10/22/2021
	Serine Protease Inhibitors					
BioCryst	Biaryl	SO	6,699,994	Granted	10/22/2001	11/09/2021
	Compounds as					
	Inhibitors					
BioCryst	Biaryl	US	6,936,719	Granted	10/22/2001	11/09/2021
	Compounds as					
	Serine Protease Inhibitors					
BioCryst	Compositions and Uses of Amidine	Australia	2015305214	Granted	08/24/2015	08/24/2035
	Derivatives					
BioCryst	Compositions and Uses of Amidine	Canada	2959026	Pending	08/24/2015	08/24/2035
	Derivatives					
BioCryst	Compositions and	EPO	15756791.8	Pending	08/24/2015	08/24/2035
	Uses of Amidine Derivatives					
BioCryst	Compositions and	Hong Kong	17113101.0	Pending	08/24/2015	08/24/2035
	Uses of Amidine					
	Derivatives					
BioCryst	Compositions and	Japan	2017-510576	Pending	08/24/2015	08/24/2035
	Uses of Amidine					
	Denvatives					

Confidential

Owner of	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date <sup>2</sup>	Projected Expiration Date <sup>3</sup>
					Q	
BioCryst	Compositions and Uses of Amidine Derivatives	US	15/505,534	Allowed	08/24/2015	08/24/2035
BioCryst	Human Plasma Kallikrein Inhibitors	Australia	2015226855	Allowed	03/09/2015	03/09/2035
BioCryst	Human Plasma Kallikrein Inhibitors	Australia	2020260400	Pending	03/09/2015	03/09/2035
BioCryst	Human Plasma Kallikrein Inhibitors	Brazil	112016020199-0	Pending	03/09/2015	03/09/2035
BioCryst	Human Plasma Kallikrein Inhibitors	Canada	2941380	Pending	03/09/2015	03/09/2035
BioCryst	Human Plasma Kallikrein Inhibitors	China	201580022369.5	Allowed	03/09/2015	03/09/2035
BioCryst	Human Plasma Kallikrein Inhibitors	Colombia	33324 (NC2016/0002647)	Granted	03/09/2015	03/09/2035
BioCryst	Human Plasma Kallikrein Inhibitors	BioCryst Human Piasma EPO 3113772 Kallikrein (15759254.4) Inhibitors	3113772 (15759254.4)	#To be validated in AL, AT, BE, BG, CH/LI, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, BS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, and TR	03/09/2015	03/09/2035

Confidential

**PATENT** REEL: 063284 FRAME: 0048

	***************************************			***************************************		Duntantat
Owner of	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date <sup>2</sup>	Expiration Date <sup>3</sup>
					R	
BioCryst	Human Plasma	Odi	20191747.3	Pending	03/09/2015	03/09/2035
	Kallikrein Inhibitors					
BioCryst	Human Plasma	Eurasia	036251	Granied	03/09/2015	03/09/2035
,	Kallikrein					
	Inhibitors					
BioCryst	Human Plasma	Eurasia	202091668	Pending	03/09/2015	03/09/2035
	Kallikrein					
	Inhibitors					
BioCryst	Human Plasma	Hong Kong	17106350.2	Pending	03/09/2015	03/09/2035
	Kallıkrein					
BioCryst	Human Plasma	India	201637034289	Pending	03/09/2015	03/09/2035
	Kallikrein					
	Inhibitors					
BioCryst	Human Plasma	Israel	247518	Pending	03/09/2015	03/09/2035
	Kallikrein					
	Inhibitors					
BioCryst	Human Plasma	Japan	6574435	Granted	03/09/2015	03/09/2035
	Kallikrein		(2016-555752)			
	Inhibitors					
BioCryst	Human Plasma	Japan	2019-149385	Pending	03/09/2015	03/09/2035
	Kallikrein					
	Inhibitors					
BioCryst	Human Plasma	Republic of	10-2016-7026786	Pending	03/09/2015	03/09/2035
	Kallikrein	Korea				
	Inhibitors					
BioCryst	Human Plasma	Malaysia	PI 2016001634	Pending	03/09/2015	03/09/2035
	Kallikrein					
	Inhibitors					

Confidential

<u>\*\*\*</u>

Owner of IP1	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date <sup>2</sup>	Projected Expiration Date <sup>3</sup>
		8			100	
BioCryst	Human Plasma Kallikrein Inhibitors	Mexico	MX/a/2016/011468	Allowed	03/09/2015	03/09/2035
BioCryst	Human Plasma Kallikrein Inhibitors	New Zealand	724250	Pending	03/09/2015	03/09/2035
BioCryst	Human Plasma Kallikrein Inhibitors	New Zealand	762034	Pending	03/09/2015	03/09/2035
BioCryst	Human Plasma Kallikrein Inhibitors	Philippines	1-2016-501750	Pending	03/09/2015	03/09/2035
BioCryst	Human Plasma Kallikrein Inhibitors	Singapore	11201607267S	Granted	03/09/2015	03/09/2035
BioCryst	Human Plasma Kallikrein Inhibitors	Singapore	10202001795 <b>X</b>	Pending	03/09/2015	03/09/2035
BioCryst	Human Plasma Kallikrein Inhibitors	South Africa	2016/06320	Pending	03/09/2015	03/09/2035
BioCryst	Human Plasma Kallikrein Inhibitors	South Africa	2019/06027	Pending	03/09/2015	03/09/2035
BioCryst	Human Plasma Kallikrein Inhibitors	S	10,125,102 (15/123,059)	Granted	03/09/2015	03/09/2035
BioCryst	Human Plasma Kallikrein Inhibitors	us	10,329,260 (15/977,129)	Granted	03/09/2015	03/09/2035

Confidential

Owner of			Patent or Application			Projected Expiration
117	THE UTIF	Country/Negron	MEHDEL	SIBIBS	Filling Date	BIEG
BioCryst	Human Plasma	US	10,633,345	Granted	03/09/2015	03/09/2035
•	Kallikrein		(16/009,943)			
	Inhibitors		( )			
BioCryst	Human Plasma	US	10,689,346	Granted	03/09/2015	03/09/2035
,	Kallikrein		(16/400,798)			
	Inhibitors					
BioCryst	Human Plasma	US	16/828,755	Pending	03/09/2015	03/09/2035
,	Kallikrein			1		
	Inhibitors					
<b>BioCryst</b>	Human Plasma	US	16/828,763	Pending	03/09/2015	03/09/2035
	Kallikrein					
	Innibitors	777	4 5 11 6 7 10 4	<b>3</b>		() A () () ()
DioClyst	Figures Fragula	0.5	10/040,000	Rimbar	03/03/2013	00/09/2000
	Kallikrein					
RioCres	Human Plasma	Australia	900559100	Pendino	9106/02/06	920/20/203
( ) ( ) ( )	Kallibrain		1	q	:	; ; ;
	Inhibitors:					
BioCryst	Human Plasma	Brazil	BR112018005843-2	Pending	09/30/2016	09/30/2036
,	Kallikrein			;		
	Inhibitors					
BioCryst	Human Plasma	Canada	2999164	Pending	09/30/2016	09/30/2036
	Kallikrein					
	Inhibitors					
BioCryst	Human Plasma	China	201680069679.7	Pending	09/30/2016	09/30/2036
	Kallikrein					
	Inhibitors					
BioCryst	Human Plasma	Colombia	NC2018/0004572	Pending	09/30/2016	09/30/2036
	Kallikrein					
	Inhibitors					

Confidential

Owner of IP	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date <sup>2</sup>	Projected Expiration Date <sup>3</sup>
					i G	
BioCryst	Human Plasma Kallikrein Inhibitors	EPO	16852664.8	Pending	09/30/2016	09/30/2036
BioCīyst	Human Plasma Kallikrein Inhibitors	Eurasia	201890862	Pending	09/30/2016	09/30/2036
BioCryst	Human Plasma Kallikrein Inhibitors	Hong Kong	18113965.4	Pending	09/30/2016	09/30/2036
BioCryst	Human Plasma Kallikrein Inhibitors	Indía	201837013301	Pending	09/30/2016	09/30/2036
BioCryst	Human Plasma Kallikrein Inhibitors	İsrael	258104	Pending	09/30/2016	09/30/2036
BioCryst	Human Plasma Kallikrein Inhibitors	Japan	2018-516461	Pending	09/30/2016	09/30/2036
BioCryst	Human Plasma Kallikrein Inhibitors	Republic of Korea	10-2018-7012013	Pending	09/30/2016	09/30/2036
BioCryst	Human Plasma Kallikrein Inhibitors	Malaysia	Pł 2018000405	Pending	09/30/2016	09/30/2036
ВюСтуя	Human Plasma Kallikrein Inhibitors	Mexico	MX/a/2018/003930	Pending	09/30/2016	09/30/2036
BioCryst	Human Plasma Kallikrein Inhibitors	New Zealand	741030	Pending	09/30/2016	09/30/2036

Confidential

Owner of IP <sup>1</sup>	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date <sup>2</sup>	Projected Expiration Date <sup>3</sup>
		0			Q	
BioCryst	Human Plasma Kallikrein Inhibitors	Philippines	1-2018-500678	Pending	09/30/2016	09/30/2036
BioCryst	Human Plasma Kallikrein Inhibitors	Singapore	11201802463Q	Granted	09/30/2016	09/30/2036
BioCryst	Human Plasma Kallikrein Inhibitors	Singapore	10202003705W	Pending	09/30/2016	09/30/2036
BioCryst	Human Plasma Kallikrein Inhibitors	South Africa	2018/02374	Pending	09/30/2016	09/30/2036
BioCryst	Human Plasma Kallikrein Inhibitors	US	10,562,850 (15/764,071)	Granted	09/30/2016	09/30/2036
BioCryst	Human Plasm Kallikrein Inhibitors	US	16/718,537	Pending	9/30/2016	9/30/2036
BioCryst	Human Plasma Kallikrein Inhibitors	Argentina	20160103021	Pending	09/30/2016	09/30/2036
BioCryst	Human Plasma Kallikrein Inhibitors	Taiwan	105131766	Pending	09/30/2016	09/30/2036
BioCryst	Prodrugs of Kallikrein Inhibitors	Australia	2017348305	Pending	10/27/2017	10/27/2037
BioCryst	Prodrugs of Kallikrein Inhibitors	Canada	3041058	Pending	10/27/2017	10/27/2037

Confidential

Owner of	Title of IP	Country/Region	Patent or Application Number	Status	
BioCryst	Prodrugs of Kallikrein Inhibitors	EPO	17864949.7		Pending
BioCryst	Prodrugs of Kallikrein Inhibitors	Hong Kong	620200036189		Pending
BioCryst	Prodrugs of Kallikrein Inhibitors	Japan	2019-522794		Pending
BioCryst	Prodrugs of Kallikrein Inhibitors	İsracl	266223		Pending
BioCryst	Prodrugs of Kallikrein Inhibitors	US	10,759,759 (16/345,503)		Granted
BioCryst	Prodrugs of Kallikrein Inhibitors	US	16/987,721		Pending
BioCryst	Benzopyrazole Compounds and Analogues Thereof	Australia	2017213768		Pending
BioCryst	Benzopyrazole Compounds and Analogues Thereof	Brazil	BR 112018015289-7	)7	
BioCryst	Benzopyrazole Compounds and Analogues Thereof	Canada	3011549		Pending

Confidential

Benzopyrazok   EPO   17748044.9   Pending	Owner of Ips  BioCryst  BioCryst	Title of IP  Benzopyrazole Compounds and Analogues Thereof Benzopyrazole Compounds and Analogues Thereof	Country/Region China China Colombia	Patent or Application Number 201780021413.X NC2018/0008916	Status Pending Pending	Filing Date <sup>2</sup> 02/01/2017 02/01/2017
Benzopyrazole Eurasia 201891703 Pending Compounds and Analogues Thereof Benzopyrazole Hong Kong 19124745.1 Pending Compounds and Analogues Thereof Benzopyrazole India 201817027818 Pending Compounds and Analogues Thereof Benzopyrazole Israel 260545 Pending Compounds and Analogues Thereof Compounds and Analogues Thereof Benzopyrazole Israel 260545 Pending Compounds and Analogues Thereof Compounds and Analogues Thereof Benzopyrazole Israel 260545 Pending Compounds and Analogues Thereof Thereof Benzopyrazole Japan 2018-539873 Pending	BioCryst	Benzopyrazołe Compounds and Analogues Thereof	EPO	17748044,9	Pending	02/01/2017
Benzopyrazole Hong Kong 19124745.1 Pending Compounds and Analogues Thereof Benzopyrazole India 201817027818 Pending Compounds and Analogues Thereof Benzopyrazole Israel 260545 Pending Compounds and Analogues Thereof Benzopyrazole Israel 260545 Pending Compounds and Analogues Thereof Benzopyrazole Japan 2018-539873 Pending Compounds and Analogues	BioCryst	Benzopyrazole Compounds and Analogues Thereof	Eurasia	201891703	Pending	02/01/2017
Benzopyrazole India 201817027818 Pending Compounds and Analogues Thereof Benzopyrazole Israel 260545 Pending Compounds and Analogues Thereof Benzopyrazole Japan 2018-539873 Pending Compounds and Analogues Thereof	BioCryst	Benzopyrazole Compounds and Analogues Theseof	Hong Kong	19124745.1	Pending	02/01/2017
Benzopyrazole Israel 260545 Pending Compounds and Analogues Thereof Benzopyrazole Japan 2018-539873 Pending Compounds and Analogues Thereof	BioCryst	Benzopyrazołe Compounds and Analogues Thereof	India	201817027818	Pending	02/01/2017
Benzopyrazole Japan 2018-539873 Pending Compounds and Analogues Thereof	BioCryst	Benzopyrazole Compounds and Analogues Thereof	[sræ]	260545	Pending	02/01/2017
	BioCryst	Benzopyrazołe Compounds and Analogues Thereof	Japan	2018-539873	Pending	02/01/2017

Confidential

BioCryst	BioCryst	BioCryst	BioCryst	BioCryst	BioCryst	BioCryst	BioCryst	Owner of IP <sup>1</sup>
Benzopyrazołe Compounds and Analogues Thereof	Benzopyrazołe Compounds and Analogues Thereof	Benzopyrazołe Compounds and Analogues Thereof	Benzopyrazołe Compounds and Analogues Theseof	Benzopyrazołe Compounds and Analogues Thereof	Benzopyrazołe Compounds and Analogues Thereof	Benzopyrazołe Compounds and Analogues Thereof	Benzopyrazole Compounds and Analogues Thereof	Title of IP
Sn	South Africa	Singapore	Philippines	New Zealand	Mexico	Malaysia	Republic of Korea	Country/Region
16/073,934	2018/05074	11201805940Q	1-2018-501537	744587	MX/a/2018/008869	PI 2018001324	10-2018-7024635	Patent or Application Number
Allowed	Pending	Status						
02/01/2017	02/01/2017	02/01/2017	02/01/2017	02/01/2017	02/01/2017	02/01/2017	02/01/2017	Filing Date <sup>2</sup>
02/01/2037	02/01/2037	02/01/2037	02/01/2037	02/01/2037	02/01/2037	02/01/2037	02/01/2037	Projected Expiration Date

Confidential

BioCryst	BioCryst	BioCryst	BioCryst	BioCryst	BioCryst	BioCryst	BioCryst	Owner of IP1
lmidazole- containing lnhibitors of ALK2 Kinase	lmidazole- containing Inhibitors of ALK2 Kinase	Imidazole- containing Inhibitors of ALK2 Kinase	Imidazole- containing Inhibitors of ALK2 Kinase	Imidazole- containing Inhibitors of ALK2 Kinase	Benzopyrazołe Compounds and Analogues Thereof	Benzopyrazołe Compounds and Analogues Thereof	Benzopyrazole Compounds and Analogues Thereof	Title of IP
China	Chile	Canada	Brazil	Australia	Taiwan	Argentina	US	Country/Region
201880052585.8	3669-2019	3066164	BR112019026517-1	2018283053	106103180	20170100240	17/003,552	Patent or Application Number
Pending	Pending	Pending	Pending	Pending	Pending	Pending	Pending	Status
06/14/2018	06/14/2018	06/14/2018	06/14/2018	06/14/2018	01/26/2017	01/30/2017	02/01/2017	Filing Date <sup>2</sup>
06/14/2038	06/14/2038	06/14/2038	06/14/2038	06/14/2038	01/26/2037	01/30/2037	02/01/2037	Projected Expiration Date <sup>3</sup>

Confidential

Inhibitors of ALK2 Kinase	BioCryst Imidazole-	BioCryst Imidazole- containing Inhibitors of ALK2 Kinase	BioCryst Imidazole- containing Inhibitors of ALK2 Kinase	BioCryst Imidazole- containing Inhibitors of ALK2 Kinase	BioCryst Imidazole- containing Inhibitors of ALK2 Kinase	BioCryst Imidazole- containing Inhibitors of ALK2 Kinase	BioCryst Imidazole- containing Inhibitors of ALK2 Kinase	Owner of Title of IP
Republic of Korea	Japan of ase	israel of ase	India of ase	Hong Kong of ase	Eurasia of ose	EPO of ase	Colombia of ase	Country/Region
19-2029-7001054	2019-568599	271109	202037000070	62020018359.3	202090052	18816547.6	NC2020/0000194	Patent or Application Number
Pending	Pending	Pending	Pending	Pending	Pending	Pending	Pending	Status
06/14/2018	06/14/2018	06/14/2018	06/14/2018	06/14/2018	06/14/2018	06/14/2018	06/14/2018	Filing Date <sup>2</sup>
06/14/2038	06/14/2038	06/14/2038	06/14/2038	06/14/2038	06/14/2038	06/14/2038	06/14/2038	Projected Expiration Date <sup>3</sup>

Confidential

8

BioCryst	BioCryst	BioCryst	BioCryst	BioCryst	BioCryst	BioCryst	BioCryst	Owner of
Imidazole- containing Inhibitors of ALK2 Kinase	lmidazole- containing lahibitors of ALK2 Kinase	Imidazole- containing Inhibitors of ALK2 Kinase	Imidazole- containing Inhibitors of ALK2 Kinase	Imidazole- containing Inhibitors of ALK2 Kinase	Imidazole- containing Inhibitors of ALK2 Kinase	lmidazole- containing Inhibitors of ALK2 Kinase	Imidazole- containing Inhibitors of ALK2 Kinase	Title of IP
Argentina	Sn	South Africa	Singapore	Philippines	New Zealand	Mexico	Malaysia	Country/Region
20180101628	16/622,816	2020/00217	11201911289W	1-2019-502781	760263	MX/a/2019/015226	PI 2019007421	Patent or Application Number
Pending	Pending	Pending	Pending	Pending	Pending	Pending	Pending	Status
06/13/2018	06/14/2018	06/14/2018	06/14/2018	06/14/2018	06/14/2018	06/14/2018	06/14/2018	Filing Date <sup>2</sup>
06/13/2038	06/14/2038	06/14/2038	06/14/2038	06/14/2038	06/14/2038	06/14/2038	06/14/2038	Projected Expiration Date <sup>3</sup>

Confidential

Owner of IP	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date <sup>2</sup>	Projected Expiration Date <sup>3</sup>
					Q	
BioCryst	lmidazole-	Taiwan	107120504	Pending	06/14/2018	06/14/2038
,	containing			;		
	Inhibitors of					
	ALK2 Kinasc					
BioCryst	Substituted	Australia	2019247471	Pending	04/05/2019	04/05/2039
	Benzofuran,					
	Benzypyrrole,					
	Benzothiophene,					
	and Structurally					
	Related					
	Complement					
	Inhibitors					
BioCryst	Substituted	Brazil	BR112020019185-3	Pending	04/05/2019	04/05/2039
	Benzofuran,					
	Benzypyrrole,					
	Benzothiophene,					
	and Structurally					
	Related					
	Complement					
	limibitors					
BioCryst	Substituted	Canada	3095628	Pending	04/05/2019	04/05/2039
	Benzofuran,					
	Benzypyrrole,					
	Benzothiophene,					
	and Structurally					
	Related					
	Complement					
	lubibitors					

Confidential

Owner of IP <sup>1</sup>	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date <sup>2</sup>	Projected Expiration Date <sup>3</sup>
Rio Creat	Cirkovitatok	a ii	25792020	Dondino	04/05/2010	04/04/2020
( ) ( )	Benzofuran,	1	3	Û	3 3 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
	Benzypyrrole,					
	Benzothiophene,					
	and Structurally					
	Related					
	Complement					•••••
	Inhibitors					•••••
BioCryst	Substituted	China	Not Yet Available	Pending	04/05/2019	04/05/2039
	Benzofuran,		(National-phase entry of			
	Benzypyrrole,		PCT/US2019/026054)			
	Benzothiophene,					
	and Structurally					
	Related					
	Complement					
	Inhibitors					
BioCryst	Substituted	Colombia	NC2020/0013840	Pending	04/05/2019	04/05/2039
	Benzofuran,					
	Benzypyrrole,					
	Benzothiophene,					
	and Structurally					•••••
	Related					
	Complement					
BioCryst	Substituted	EBO OGE	197807381	Pendino	04/05/2019	04/05/2039
1	Benzofuran,			ŧ		
	Benzypyrrole,					
	Benzothiophene,					
	and Structurally					
	Related					
	Complement					
	Inhibitors					

Confidential

BioCryst	BioCryst	BioCryst	BioCryst	Owner of IP1
Substituted Benzofuran, Benzypyrrole, Benzothiophene, and Structurally Related Complement Inhibitors	Substituted Benzofuran, Benzypyrrole, Benzothiophene, and Structurally Related Complement Inhibitors	Substituted Benzofuran, Benzypyrrole, Benzothiophene, and Structurally Related Complement Inhibitors	Substituted Benzofuran, Benzypyrrole, Benzothiophene, and Structurally Related Complement Inhibitors	Title of IP
india	Hong Kong	Guatemała	Eurasia	Country/Region
202017048130	Not Yet Available	A-2020-00153	202092383	Patent or Application Number
Pending	Filing Authorized	Pending	Pending	Status
04/05/2019	04/05/2019	04/65/2019	04/05/2019	Filing Date <sup>2</sup>
04/05/2039	04/05/2039	04/05/2039	04/05/2039	Projected Expiration Date <sup>3</sup>

Confidential

BioCryst	BioCryst	BioCryst	BioCryst	Owner of IP <sup>1</sup>
Substituted Benzofuran, Benzypyrrole, Benzothiophene, and Structurally Related Complement Inhibitors	Substituted Benzofuran, Benzypyrrole, Benzothiophene, and Structurally Related Complement Inhibitors	Substituted Benzofuran, Benzypyrrole, Benzothiophene, and Structurally Related Complement Inhibitors	Substituted Benzofuran, Benzypyrrole, Benzothiophene, and Structurally Related Complement Inhibitors	Title of IP
Republic of Korea	Japan	[srac]	Indonesia	Country/Region
10-2020-7031889	2020-554437	277787	P00202008112	Patent or Application Number
Pending	Pending	Pending	Pending	Status
04/05/2019	04/05/2019	04/05/2019	04/05/2019	Filing Date <sup>2</sup>
04/05/2039	04/05/2039	04/05/2039	04/05/2039	Projected Expiration Date <sup>3</sup>

Confidential

BioCryst	BioCryst	BioCryst	BioCryst	Owner of Ip <sup>3</sup>
Substituted Benzofuran, Benzypyrrole, Benzothiophene, and Structurally Related Complement Inhibitors	Substituted Benzofuran, Benzypyrrole, Benzothiophene, and Structurally Related Complement Inhibitors	Substituted Benzofuran, Benzypyrrole, Benzothiophene, and Structurally Related Complement Inhibitors	Substituted Benzofuran, Benzypyrrole, Benzothiophene, and Structurally Related Complement Inhibitors	Title of IP
Peru	New Zealand	Mexico	Malaysia	Country/Region
001534-2020	769362	MX/a/2020/010508	PI 2020004888	Patent or Application Number
Pending	Pending	Pending	Pending	Status
04/05/2019	04/05/2019	04/05/2019	04/05/2019	Filing Date <sup>2</sup>
04/05/2039	04/05/2039	04/05/2039	04/05/2039	Projected Expiration Date <sup>3</sup>

Confidential

					***************************************	Projected
Owner of	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date <sup>2</sup>	Expiration Date <sup>3</sup>
ВіоСтуя	Substituted Benzofuran,	Philippines	1-2020-551589	Pending	04/05/2019	04/05/2039
	Benzypyrrole,					
	Benzothiophene,					
	Related					
	Complement					
	Inhibitors					
BioCryst	Substituted	Singapore	11202008972 <b>W</b>	Pending	04/05/2019	04/05/2039
	Benzynymole					
	Benzothionhene					
	and Structurally					
	Related					
	Complement					
BioCryst	Substituted	South Africa	2020/06058	Pending	04/05/2019	04/05/2039
	Benzofuran,					
	Benzypyrrole,					
	Benzothiophene,					
	and Structurally					
	Related					
	Complement Inhibitors					
BioCryst	Substituted	SÜ	16/511,642	Pending	04/05/2019	04/05/2039
	Benzofuran,			:		
	Benzypyrrole,					
	Benzothiophene,					
	and Structurally					
	Related					
	Complement					
	Inhibitors					

Confidential

Owner of	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date <sup>2</sup>	Projected Expiration Date <sup>3</sup>
)				\$		
BioCry≭	Substituted Benzofuran,	Argentina	20190100905	Pending	04/05/2019	04/05/2039
	Benzypyrrole,					
	Benzothiophene,					
	and Structurally					
	Related					
	Complement					
	Inhibitors					
BioCryst	Substituted	900	2019/37319	Pending	04/03/2019	04/03/2039
	Benzynymole					
	Benzothionhene					
	and Structurally					
	Related					
	Complement					
BioCryst	Substituted	Lebanon	11646	Granted	04/05/2019	04/05/2039
9,	Benzofuran,		(1134)			
	Benzypyrrole,					
	Benzothiophene,					
	and Structurally					
	Related					
	Complement					
BioCryst	Substituted	Pakistan	206/2019	Pending	04/04/2019	04/04/2039
,	Benzofuran,			1		
	Benzypyrrole,					
	Benzothiophene,					
	and Structurally					
	Related					
	Complement					
	Inhibitors					

Confidential

Owner of	Title of IP	Country/Region	Patent or Application	Status	Filine Data <sup>2</sup>	Projected Expiration Date3
	N BOTH, O'L LA	Country	1 TOTAL DE	Classes	7 222150 De 100 100 100 100 100 100 100 100 100 10	
BioCryst	Substituted Benzofuran	Paraguay	27283/2019	Pending	04/05/2019	
	Benzypyrrole,					
	Benzothiophene.					
	and Structurally					
	Related					
	Complement					
	Inhibitors					
BioCryst	Substituted	Taiwan	1080111855	Pending	04/03/2019	04/03/2039
	Benzofuran,					
	Benzypymole,					
	Benzothiophene,					
	and Structurally					
	Related					
	Complement					
	Inhibitors					
BioCryst	Substituted	Uruguay	38174	Pending	04/05/2019	04/05/2039
	Benzofuran,					
	Benzypymole,					
	Benzothiophene.					
	and Structurally					
	Related					
	Complement					
5	MENDHOIS C. 1.	X (C)	20202020202020	<del>;</del>	*********	4
RIOCIVSE	Crystallane Salts	CO.	PC1/US/019/059585	Pending	81/01/2019	11/01/2859
	of a Plasma					
	Kallikrein					
	luhibitor					
BioCryst	Crystalline Salts	US	10,662,160	Granted	11/01/2019	11/01/2039
	of a Plasma		(16/671,649)			
	Kallikrein					
	Inhibitor					

Confidential

59

Owner of IP:	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date <sup>2</sup>	Projected Expiration Date <sup>3</sup>
BioCryst	Crystalline Salts of a Plasma Kallikrein Inhibitor	US	16/784,016	Pending	11/01/2019*	11/01/2039
BioCryst	Crystalline Salts of a Plasma Kallikrein Inhibitor	Argentina	20190103187	Pending	10/31/2019	10/31/2039
BioCryst	Crystalline Salts of a Plasma Kallikrein Inhibitor	GCC	2019/38571	Pending	10/31/2019	10/31/2039
BioCryst	Crystalline Salts of a Plasma Kallikrein Inhibitor	Lebanon	11781 (3311)	Granted	10/51/2019	10/31/2039
BioCryst	Crystalline Salts of a Plasma Kallikrein Inhibitor	Pakistan	731/2019	Pending	11/01/2019	11/01/2039
BioCryst	Crystalline Salts of a Plasma Kallikrein Inhibitor	Paraguay	91831/2019	Pending	11/01/2019	11/01/2039
BioCryst	Crystalline Salts of a Plasma Kallikrein Inhibitor	Taiwan	108139655	Pending	£1/01/2019	<b>!!</b> /01/2039
ВіоСтуя	Crystalline Salts of a Plasma Kallikrein Inhibitor	Uruguay	38438	Pending	\$0/31/2019	10/31/2039

Confidential

Owner of	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date <sup>2</sup>	Projected Expiration Date <sup>3</sup>
					,	
BioCryst	Plasma Kallikrein	US	PCT/US2020/027287	Pending	04/08/2020	04/08/2040
	Inhibitors and			;		
	Methods of Use					
	Thereof in Ocular					
	Disorders					
BioCryst	Dosing Regimens	SN	PCT/US2020/044037	Pending	07/29/2020	07/29/2040
	for Oral			;		
	Complement					
	Factor D					
	Inhibitors					
BioCryst	Dosing Regimens for Oral	Argentina	20200102161	Pending	07/31/2020	07/31/2040
	Complement					
	Factor D					
1	IBBIDIOIS	222	~ ~ ~ · · · · · · · · · · · · · · · · ·	j 1.	o Tien ianan	V - (2012)
B‰€.īýst	for Oral	טנגני	2020/401889	rending	07/28/2020	0402/82//0
	Complement					
	Factor D					
	Inhibitors					
BioCryst	Dosing Regimens for Oral	Lebanon	2155	Pending	07/27/2020	07/27/2040
	Complement					
	Factor D					
	Inhibitors					
BioCryst	Dosing Regimens	Pakistan	498/2020	Pending	07/29/2020	07/29/2040
	for Oral					
	Complement					
	Factor D					
	Inhibitors					

Confidential

5